1. Home
  2. ZYME vs ELME Comparison

ZYME vs ELME Comparison

Compare ZYME & ELME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ZYME
  • ELME
  • Stock Information
  • Founded
  • ZYME 2003
  • ELME 1960
  • Country
  • ZYME United States
  • ELME United States
  • Employees
  • ZYME N/A
  • ELME N/A
  • Industry
  • ZYME Biotechnology: Pharmaceutical Preparations
  • ELME Real Estate Investment Trusts
  • Sector
  • ZYME Health Care
  • ELME Real Estate
  • Exchange
  • ZYME Nasdaq
  • ELME Nasdaq
  • Market Cap
  • ZYME 1.2B
  • ELME 1.5B
  • IPO Year
  • ZYME 2017
  • ELME N/A
  • Fundamental
  • Price
  • ZYME $18.04
  • ELME $16.77
  • Analyst Decision
  • ZYME Strong Buy
  • ELME Hold
  • Analyst Count
  • ZYME 8
  • ELME 5
  • Target Price
  • ZYME $24.00
  • ELME $14.25
  • AVG Volume (30 Days)
  • ZYME 668.9K
  • ELME 873.7K
  • Earning Date
  • ZYME 11-06-2025
  • ELME 10-23-2025
  • Dividend Yield
  • ZYME N/A
  • ELME 4.30%
  • EPS Growth
  • ZYME N/A
  • ELME N/A
  • EPS
  • ZYME N/A
  • ELME N/A
  • Revenue
  • ZYME $122,867,000.00
  • ELME $245,911,000.00
  • Revenue This Year
  • ZYME $107.76
  • ELME N/A
  • Revenue Next Year
  • ZYME $2.35
  • ELME $8.14
  • P/E Ratio
  • ZYME N/A
  • ELME N/A
  • Revenue Growth
  • ZYME 95.94
  • ELME 4.59
  • 52 Week Low
  • ZYME $9.03
  • ELME $13.95
  • 52 Week High
  • ZYME $19.50
  • ELME $18.08
  • Technical
  • Relative Strength Index (RSI)
  • ZYME 65.50
  • ELME 50.96
  • Support Level
  • ZYME $18.21
  • ELME $16.67
  • Resistance Level
  • ZYME $19.10
  • ELME $16.87
  • Average True Range (ATR)
  • ZYME 0.69
  • ELME 0.12
  • MACD
  • ZYME 0.02
  • ELME 0.00
  • Stochastic Oscillator
  • ZYME 56.97
  • ELME 56.16

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

About ELME Elme Communities

Elme Communities is a real estate investment trust engaged in owning and operating properties in the greater Washington DC metropolitan area. The company's real estate portfolio is comprised of office, retail, and multifamily properties located near transportation nodes. Washington REIT derives nearly all of its income in the form of rental revenue from tenants organized into long-term leases. The company's office assets contribute the majority of this income, while the rest is split fairly evenly between its retail and multifamily locations. Washington REIT's tenants are banking, consulting, law, and financial services firms.

Share on Social Networks: